Thrombosis and Thromboembolism

Overview

Learn Now: Thrombosis CME from the Experts

This online CME course from the North American Thrombosis Forum provides a comprehensive review of the most significant changes and advances impacting the care of patients who have — or are at risk for — thrombotic disorders. World-renowned experts and leading clinical faculty share key updates on the prevention, diagnosis, and treatment of thrombosis and related conditions.

Thrombosis and Thromboembolism is continuing medical education that will help you to:

• Identify the etiology and pathophysiology of atherothrombosis
• Recognize the link between inflammation and thrombotic illnesses
• Explain new tools for stroke prevention and prediction in atrial fibrillation
• Identify the optimal duration of anticoagulation for PE and DVT
• Provide advanced therapies such as thrombolysis, catheter-directed therapy, and surgical embolectomy
• Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
• Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
• Manage a high-risk pregnancy
• And more…

Topics / Speakers

Novel Targets for Atherosclerosis Prevention

What's New with TG and AngPTL3 - Aruna D. Pradhan, MD, MPH, MSc

What’s New with Lp(a) - Samia Mora, MD

What's New with LDL and ApoB - Jorge Plutzky, MD

What's New with Inflammatory Targets - Paul M. Ridker, MD, MPH

Discussion/Q&A - John F. Keaney, Jr., MD - Moderator

Peripheral Arterial Disease

PAD – Pathways for Optimizing Cardiovascular and Limb Outcomes - Marc P. Bonaca, MD, MPH

Discussion/Q&A - Marie D. Gerhard-Herman, MD - Moderator

Heart Failure

Heart Failure and Venous Thromboembolism - Samuel Z. Goldhaber, MD

More Than Just Diabetes and Heart Failure – SGLT2 - Deepak L. Bhatt, MD, MPH

More Than Just Diabetes and Heart Failure – GLP1 - Brendan M. Everett, MD, MPH

Heart Failure – Reduced Ejection Fraction - Marc A. Pfeffer, MD, PhD

Discussion/Q&A - Akshay Suvas Desai, MD, MPH - Moderator

Heart Failure – Preserved Ejection Fraction - Scott D. Solomon, PhD

Heart Failure – Middle-of-the-Road Ejection Fraction – Navigating the Alphabet Soup - Michele A. Hamilton, MD

CMR Imaging of Imaging of Heart Failure - Raymond Y. Kwong, MD, MPH

Atrial Fibrillation & Coronary Disease

Dual Antiplatelet Therapy and Anticoagulation - Michelle L. O'Donoghue, MD, MPH

How to Manage the Anticoagulation Around Ablation and Cardioversions and Watchmans for AF - Bruce A. Koplan, MD

Anticoagulation

Dose-Reduced Direct Oral Anticoagulants – Efficacy and Safety - Behnood Bikdeli, MD, MS

Duration of Anticoagulation – Arterial Thrombosis – Navigating Limitations in Data and Variations in Practice - Teresa Carman, MD, RPVI, MSVM

Duration of Anticoagulation – Venous Thrombosis - Gregory Piazza, MD, MS

Novel Anticoagulation Targets – Factor XI and XII Inhibitors - Jeffrey I. Weitz, MD, FRCPC, FACP, FRSC, FCCP, FACC, FESC, FCAHS, FAHA, FSVM, FCCS

Discussion/Q&A - Samuel Z. Goldhaber, MD - Moderator

Racial Disparities in Arterial and Venous Thrombosis

Racial Disparities in Healthcare - Cassandra M. Pierre, MD, MSc, MPH

Racial Disparities in Arterial and Venous Thrombosis - Karlyn A. Martin, MD, MS

Discussion/Q&A - Gregory Piazza, MD, MS - Moderator

Genetics

VTE Prediction – Using Genetics as a Powerful Tool - Nicholas A. Marston, MD, MPH

Clonal Hematopoiesis of Indeterminate Potential (CHIP) – Association with VTE & PAD - Peter Libby, MD

Discussion/Q&A - Gregory Piazza, MD, MS - Moderator

Covid and Thrombosis

COVID and Thrombosis – Mechanisms and Epidemiology - Gregory Piazza, MD, MS

Prevention of VTE in COVID-19 Patients - Behnood Bikdeli, MD, MS

Discussion/Q&A - Samuel Z. Goldhaber, MD - Moderator

VTE Prevention

VTE Prophylaxis for Orthopedic Surgery - Samuel Z. Goldhaber, MD

Discussion/Q&A - Ebrahim Barkoudah, MD, MPH - Moderator

PE Reperfusion

Device Therapy for PE Reperfusion – Navigating a Rapidly Changing Landscape - Gregory Piazza, MD, MS

Systemic Fibrinolysis (PEITHO-3) - Samuel Z. Goldhaber, MD

Adventures with Hypertrophic Cardiomyopathy – 1958-2022 - Eugene Braunwald, MD

Pulmonary Hypertension and Thrombosis

Chronic Thromboembolic Pulmonary Hypertension - Bradley A. Maron, MD

Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension - Jane A. Leopold, MD, FACC, FAHA, FSCAI

Post-Thrombotic Syndrome

Post-thrombotic Syndrome – Epidemiology and Medical Therapy - Susan R. Kahn, MD, MSc, FRCPC, ABIM

Intervention, Acute Intervention, and Chronic Venous Obstructive Disease - Suresh Vedantham, MD

Discussion/Q&A - Arvind K. Pandey, MD - Moderator

VTE and Cancer

Vascular Cardio-Oncology - Javid Moslehi, MD

Prevention of Thrombotic Complications of Cancer and Cancer Therapy - Simon Mantha, MD, MPH

Treatment of Cancer-Associated Thrombosis - Michael B. Streiff, MD

Discussion/Q&A - Jean Connors, MD - Moderator

Faculty

Speakers

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and North American Thrombosis Forum. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

Designation

Oakstone Publishing designates this enduring material for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Nurses Credentialing Center

Oakstone Publishing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is approved for 12 contact hours.

Physician Assistants

The National Commission on Certification of Physician Assistants (NCCPA) states that AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification. We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.

Date of Original Release: December 31, 2022
Date Credits Expire: December 31, 2025
Estimated Time to Complete: 12 hours

CME credit is awarded upon successful completion of a course evaluation and post-test.

Learning Objectives

At the conclusion of this activity, you will be able to:

• Identify the etiology and pathophysiology of atherothrombosis
• Recognize the link between inflammation and thrombotic illnesses
• Explain new tools for stroke prevention (and stroke prediction) in atrial fibrillation
• Identify the optimal duration of anticoagulation for PE and DVT
• Provide advanced therapy beyond anticoagulation in PE and DVT: thrombolysis, catheter-directed therapy, surgical embolectomy
• Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
• Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
• Manage a high-risk pregnancy

Intended Audience

This educational activity was designed for physicians, nurse practitioners (NPs), and physician assistants (PAs) interested in changes and advances impacting the care of patients who have — or are at risk for — thrombotic disorders.

Quick Facts

Provider: North American Thrombosis Forum

Credits: Earn a maximum of 12 AMA PRA Category 1 Credits™